{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-070158","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.129939+00:00","generated_at":"2026-06-04T14:54:25.681283+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Forte Biosciences reports FY 2023 net loss of $31.5M; FB-102 advances to MAD cohort","bullets":["Net loss of $31.5M ($1.00 per share) vs. $13.9M ($0.80) in FY 2022, driven by increased R&D spend.","R&D expenses rose to $21.9M from $5.6M, primarily due to FB-102 manufacturing and clinical costs.","Cash and equivalents of $37.1M at year-end 2023, down from $41.1M at end of 2022.","FB-102 Phase 1 SAD portion completed; multiple ascending dose (MAD) cohorts now dosing.","Shares outstanding of 36.3M as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-070158","json":"https://secwatch.observer/filing/0001193125-24-070158.json","markdown":"https://secwatch.observer/filing/0001193125-24-070158.md","text":"https://secwatch.observer/filing/0001193125-24-070158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/0001193125-24-070158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/d784785d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:54:25.681283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"232d3d18af9704d309012ad8b43e8ae4624c5fde","claim":"Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income $ (31,476 ), EPS $ (1.00 ).","evidence_excerpt":"On March 18, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/0001193125-24-070158-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Net income","value":"$ (31,476 )"},{"label":"EPS","value":"$ (1.00 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}